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Background: Epidermal growth factor receptor (EGFR)-activating mutations are major determinants in predicting
the tumor response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). Noninvasive test for
the detection of EGFR mutations is required, especially in NSCLC patients from whom tissue is not available. In this
study, we assessed the feasibility of detection of EGFR mutations in free DNA circulating in plasma.
Methods: Plasma samples of 60 patients with partial response to gefitinib were analyzed to detect EGFR-activating
mutations in exons 19 and 21. Forty (66.7%) of patients had tumor EGFR mutation results. EGFR mutations in plasma
were detected using the peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping method. All
clinical data and plasma samples were obtained from 11 centers of the Korean Molecular Lung Cancer Group (KMLCG).
Results: Of the 60 patients, 39 were female and the median age was 62.5 years. Forty-three patients never smoked, 53
had adenocarcinomas, and seven had other histologic types. EGFR-activating mutation was detected in plasma of 10
cases (exon 19 deletion in seven and exon 21 L858R point mutation in three). It could not be found in plasma after
treatment for 2 months. When only patients with confirmed EGFR mutation in tumor were analyzed, 17% (6 of 35) of
them showed positive plasma EGFR mutation and the mutation type was completely matched with that in tumor.
There was no statistically significant difference in clinical parameters between patients with EGFR mutations in plasma
and those without EGFR mutations.
Conclusions: The detection rate of EGFR mutations from plasma was not so high despite highly sensitive EGFR
mutation test suggesting that more advances in detection methods and further exploration of characteristics of
circulating free DNA are required.
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Epidermal growth factor receptor (EGFR) mutations, such
as deletions in exon 19 and point mutations in exon 21, are
considered the most reliable predictive factors of outcome
after treatment of non-small cell lung cancer (NSCLC) with
EGFR tyrosine kinase inhibitors (EGFR-TKIs). Gefitinib was
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reproduction in any medium, provided the orresults of a phase III landmark study, the Iressa Pan-Asia
Study (IPASS), which showed that gefitinib conferred a sur-
vival benefit in EGFR mutation-positive patients over con-
ventional chemotherapy [1]. The trial clearly showed that
the selection of EGFR-TKIs should be based on molecular
markers, not on clinical characteristics. Since then, given
that many patients cannot receive second-line therapy after
first-line failure because of their generally deteriorating con-
dition, EGFR mutation testing is requested more frequently
at the time of diagnosis for patients with adenocarcinoma.
Indeed, a European workshop on EGFR mutation testing in
NSCLC recommended testing at diagnosis, or at relapse,
whenever possible, although no gold standard testing
method was chosen [2].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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often too little tissue available to examine EGFR status
as most are obtained by small needle biopsy or
extracted from body fluids rather than via a more ag-
gressive surgical approach. Many investigators have
tried to solve this problem, leading to the development
of more sensitive techniques to detect EGFR muta-
tions, such as the scorpion-amplified refractory muta-
tion system (SARMS) and the peptide nucleic acid
(PNA)-mediated polymerase chain reaction (PCR)
clamping method [3-18]. In addition, it is suggested
that the plasma of cancer patients contains circulating
free DNA (cfDNA) originating from necrotic tumor
cells sloughed from the tumor mass or from circulat-
ing tumor cells [19-21]. Attempts to detect EGFR mu-
tations in cfDNA using these sensitive techniques are
currently in progress. If proven feasible and reliable,
the cfDNA test may have broad clinical applications
because it is non-invasive, convenient and can be
performed repeatedly. In addition, the test could help
diagnose lung cancer in cases when an adequate tissue
sample is difficult to obtain. Over the past several
years, many reports have shown promising results and
have supported the feasibility of the test [22-33]. How-
ever, the optimal methodology for mutation detection
from cfDNA and the possibility for the replacement of
tumor tissue to blood sample still need to be confirmed.
In the present study, we examined the status of EGFR
mutations in cfDNA isolated from plasma samples by a
PNA-mediated PCR clamping method (PNA test) to




The prospective multicenter study was conducted to
analyze EGFR mutations in plasma samples. Sixty patients
with advanced NSCLC were recruited from 11 hospitals of
the Korean Molecular Lung Cancer Group (KMLCG) be-
tween May 2010 and March 2011. All participants had
histological or cytological confirmation of advanced NSCLC
and showed a partial response to gefitinib as a second-line
therapy without regard to the EGFR mutation status. Writ-
ten informed consents for the use of their blood were
obtained from all patients. The study protocol was ap-
proved by the Ethical Review Committee of 11 institutions
(Korea Cancer Center Hospital, Korea University Guro
Hospital, Daegu Catholic University Medical Center, Pusan
National University Hospital, Inje University Busan Paik
Hospital, Asan Medical Center, Wonkwang University Hos-
pital, Chonnam National University Hwasun Hospital,
Chonbuk National University Hospital, Chungnam Na-
tional University Hospital, Hallym University Medical Cen-
ter, Konkuk University Medical Center).Plasma sample collection and DNA extraction
Whole blood specimens from patients were collected
in ethylenediaminetetraacetic acid tubes before and
2 months after the initiation of gefitinib administration
and centrifuged at 3000 rpm for 5 minutes. The super-
natants were collected and centrifuged at 3000 rpm for
5 minutes. The final supernatants were transferred to
Eppendorf tubes and stored at −70°C until DNA ex-
traction. DNA was extracted from 1–2 ml of super-
natant with a DNeasy blood kit (Qiagen) according to
the manufacturer’s instructions. The final elution vol-
ume for DNA extraction was 60 μl and the amount of
plasma DNA used for mutation testing was 30 ng.
PNA-mediated real-time PCR clamping method to detect
deletions in EGFR exon 19 and L858R point mutations in
EGFR exon 21
Plasma DNA was analyzed using the PNAClampTM EGFR
Mutation Detection kit (PANAGENE, Inc., Daejeon, Korea)
as described in a previous retrospective study [34]. All reac-
tions were conducted in a 20-μl volume using template
DNA, primers and PNA probe set, and SYBR Green PCR
master mix. All reagents were included in the kit. Real-time
PCR reactions were performed using a CFX 96 instrument
(Bio-Rad, USA). PCR cycling commenced with a 5 min
hold at 94°C followed by 40 cycles at 94°C for 30 s, 70°C for
20 s, 63°C for 30 s, and 72°C for 30 s. Two EGFR mutation
types were detected using PNA-mediated real-time PCR.
The efficiency of PCR clamping was determined by meas-
uring the cycle threshold (Ct) value. Ct values for the con-
trol and mutation assays were obtained by observing the
SYBR Green amplification plots. The delta Ct (ΔCt) value
was calculated (control Ct − sample Ct), ensuring that the
sample and control Ct values were from the test and wild-
type control samples. The cut-off ΔCt was defined as 2 for
both the G746_A750 deletion and the L858R point
mutation.
Tumor mutation data
At time of blood collection, we reviewed the EGFR muta-
tion status in patient matched tumor tissue. By the direct
sequencing used in routine practice at each institution to
established EGFR mutation status in tumor tissue, forty
tumor specimens were analyzed for EGFR mutations be-
fore gefitinib.
Statistical analyses
The relationship between EGFR mutations and demo-
graphic and clinical features, including age, gender,
histological type, performance status (PS), smoking sta-
tus, TNM stage and response to gefitinib, was analyzed
using Pearson’s chi-square test or Fisher’s exact test.
Two-sided P values <0.05 were considered statistically
Table 2 EGFR mutational status in plasma DNA samples
Positive Negative
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sion 17.0 (SPSS Inc., Chicago, IL, USA).EGFR mutation EGFR mutation
(n = 10) (n = 50)
Exon 19 deletion 7 (70.0%) -
Exon 21 point mutation 3 (30.0%) -Results
Patient characteristics
The clinical characteristics of the 60 patients are shown in
Table 1. The median age was 62.5 years (range: 38–84 years).
Thirty-nine (65.0%) of the patients were female and 21
(35.0%) were male. Forty-three patients (71.7%) were non-
smokers. Fifty patients (83.3%) had good PS. The most com-
mon histological subtype was adenocarcinoma (53 patients,
88.3%) and the majority of patients (88.3%) had stage IV dis-
ease. As aforementioned, all the patients received second-
line gefitinib treatment and showed partial response.Detection of EGFR mutations in plasma
EGFR mutations were identified in 10/60 (16.7%) plasma
samples by PNA testing. Of these, seven (70.0%) wereTable 1 Clinical characteristics of 60 patients










Current smoker 6 (10.0%)
WHO Performance status
Normal activity 23 (38.3%)
Restricted activity 27 (45.0%)
In bed < 50% of the time 9 (15.0%)











Abbreviations: ADC adenocarcinoma, SQC squamous cell carcinoma, LCC large
cell carcinoma, NSCLC NOS non-small cell lung cancer not otherwise specified.in-frame deletions within exon 19 and three (30.0%)
were arginine-to-leucine substitutions at amino acid 858
in exon 21 (L858R) (Table 2). After 2 months of treat-
ment, a repetition of the test in EGFR mutation-positive
patients showed that none had EGFR mutations.Comparison of matched tumor sequencing and plasma
EGFR mutations
To evaluate the accuracy of the results of the PNA test,
we compared plasma EGFR mutations with tumor se-
quencing in 40 paired donor-matched plasma and tumor
tissue specimens. EGFR mutations were detected in the
plasma samples of six (15.0%) patients, including four
deletions in exon 19 and two point mutations in exon
21. In the donor-matched tumor tissues, 35 mutations
were detected (87.5%) by using direct sequencing, in-
cluding 18 in exon 19 and 17 in exon 21. Of the patients
with plasma EGFR mutations, mutations of identical
exon site were detected in the matched tumor tissues
(Table 3).Correlation between EGFR mutation status assessed by
PNA-mediated real-time PCR clamping and clinical
features
EGFR mutations in plasma were detected more fre-
quently in females (17.9% vs. 14.3% in male), non-
smokers (18.6% vs. 11.8% in current/former smokers)
and patients with stage IIIB disease (25.0% vs. 17.0% in
stage IV). In addition, the overall mutation detection
rate at the institute at which the central laboratory was
located, and where sample processing did not require
shipment, was relatively higher than that at the other in-
stitutes (23.8% vs. 12.8%); however, there were no statis-
tically significant differences between the number of
patients with EGFR mutations in plasma and those with-
out (Table 4).Table 3 EGFR mutational status in the paired specimens
of plasma and tumor tissue
N = 40 Plasma EGFR mutation
Positive Negative
Tissue EGFR mutation positive 6 29
negative 0 5










(n = 10) (n = 50)
Age
Median, years 60.5 63.0 0.76
Range 51-76 38-84
Gender
Female 7 (70.0%) 32 (64.0%) 1.00
Male 3 (30.0%) 18 (36.0%)
Smoking history
Nonsmoker 8 (80.0%) 35 (70.0%) 0.67
Ex-smoker 1 (10.0%) 10 (20.0%)
Current smoker 1 (10.0%) 5 (10.0%)
WHO Performance status
Normal activity 4 (40.0%) 19 (38.0%) 0.94
Restricted activity 4 (40.0%) 23 (46.0%)
In bed < 50% of the time 2 (20.0%) 7 (14.0%)
In bed > 50% of the time - 1 (2.0%)
Tumor histology
ADC 9 (90.0%) 44 (88.0%) 0.83
SQC - 3 (6.0%)
LCC - 1 (2.0%)
NSCLC NOS 1 (10.0%) 1 (2.0%)
Others - 1 (2.0%)
Stage
IIIA - 3 (6.0%) 0.64
IIIB 1 (10.0%) 3 (6.0%)
IV 9 (90.0%) 44 (88.0%)
Central labotory
on-site 5 (50.0%) 16 (32.0%) 0.30
off-site 5 (50.0%) 34 (68.0%)
Abbreviations: ADC adenocarcinoma, SQC squamous cell carcinoma LCC large
cell carcinoma, NSCLC NOS non-small cell lung cancer not otherwise specified.
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Direct sequencing of amplified DNA products using
Sanger’s method is the most popular test for detecting
EGFR mutations. However, this method is limited by
low sensitivity (meaning that the mutant DNA must
represent greater than 25% of the total DNA), and re-
quires multiple steps to be performed over several days
[15]. Furthermore, in patients with advanced NSCLC,
tumor tissue is not always available for EGFR mutation
testing either because only small amounts of tissue are
collected or because the tissues collected have very low, ornon-existent, tumor content . For these reasons, new tech-
niques are needed for more sensitive and rapid detection.
Several new techniques, including SARMS, Taqman
PCR, and denaturing high-performance liquid chroma-
tography (dHPLC) have been introduced, although none
have been adopted as a standard method for detecting
EGFR mutations [4,5,9-11,13,14,16,22-24,26-28,30-33].
Peptide nucleic acid (PNA) is an artificial polymer with
the properties of both nucleic acids and proteins. PNA
can bind tightly to complementary sequences in DNA
because of a lack of electrostatic repulsion. Therefore,
when a PNA oligomer, designed to detect an EGFR mu-
tation and to bind to the antisense strand of the wild-
type EGFR gene, is used for real-time PCR, amplification
is rapid and sensitive and displays similar sensitivity to
SARMS. Several studies using this novel method have
been published [8,17,34,35], however, to our knowledge,
there are no reports showing detection of EGFR muta-
tions in cfDNA extracted from the plasma of NSCLC
patients using PNA-mediated real time PCR clamping.
In the present study, the detection rate of EGFR muta-
tions in cfDNA was 16.1%. This is somewhat lower than
that reported previously, which ranges from 20% to 73%
(Table 5) [16,24,26-28,32]. Mutation detection rates can
differ between subjects and between methods. Around
50–60% of Asian patients and 20–30% of Western pa-
tients with adenocarcinomas are expected to carry acti-
vating EGFR mutations, while a negligible proportion of
patients with other lung cancer histology are expected
to carry such mutations. Therefore, the EGFR mutation
detection rate can be estimated from the clinical and
demographic parameters, including race and histology,
of the study subjects. If we assume that 50% of Asian
adenocarcinoma patients carry EGFR mutations, the
expected detection rate in an Asian study population
comprising 80% adenocarcinoma patients should be
40%. In this context, the results of several previous studies
suggesting that the EGFR mutation test in cfDNA might
be equivalent to that in tissue exceed the expected rate of
EGFR positivity. Hence, it is difficult to accept these al-
though the tests used in those studies are highly sensitive
and always performed with the utmost precision. In
addition, other reports published detection rates around
20% [26,27], which is similar to our report, and still EGFR
mutation testing in cfDNA has not been introduced in
clinical practice in spite of such promising results over sev-
eral years. Therefore, more data are required to evaluate
the suitability of the cfDNA test and assess whether it can
replace the traditional tumor tissue test.
The T790M mutation was not detected in any of the
samples that were positive for activating EGFR mutations,
although one report showed that low levels of T790M were
detected in pretreatment tumor samples from 10/26 pa-
tients (38%) [24]. The detection rate of T790M seems to be
Table 5 Previous reports on EGFR mutation test from circulating free DNA
Year Authors Subjects DNA concentration Mutation test Detection rate







2008 Maheswaran S, et al. [24] Western N/A SARMS 39% (7/18)
EGFR mutant patients








ORR : 36% (37/102)
2009 Mack PC, et al. [26] Western/Asian : 96/4% 2.3 ng/μL





2009 Kuang Y, et al. [25] Western 52.3 ng/μL (range,
10–163 ng/μL )
SARMS and WAVE/Surveyor 54% (29/54)




2010 Brevet M, et al. [31] Western N/A Mass spectrometry genotyping




























Table 5 Previous reports on EGFR mutation test from circulating free DNA (Continued)
ORR : 30%
2011 Jiang B, et al. [30] Asian Minimum 4 ng/μL
(range, 11–66 ng/μL )




2011 Taniguchi K, et al. [32] Asian N/A BEAMing 72.7% (32/44)
EGFR mutant patients





Abbreviations: ADC adenocarcinoma, SARMS scorpion-amplified refractory mutation system, PCR polymerase chain reaction, dHPLC denaturing high-performance liquid chromatography, BEAMing beads, emulsion,


















Kim et al. Journal of Experimental & Clinical Cancer Research 2013, 32:50 Page 7 of 8
http://www.jeccr.com/content/32/1/50closely associated with the sensitivity of the EGFR mutation
test. A study using the BEAMing (beads, emulsion, amplifi-
cation, and magnetics) method showed that the proportion
of T790M within activating mutations ranged from 13.3–
94.0%, and calculated that the T790M peak within the mu-
tant allele fraction would range from 0.1–1% in cfDNA
[32]. Therefore, even with a higher sensitivity permitting
detection of 1% mutant DNA, as is reached with SARMS
and PNA-based PCR clamping, detection of the T790M
mutation in cfDNA remains difficult. This suggests that cir-
culating tumor cells (CTC) would be a better alternative
source material in which to detect the T790M mutation,
and for predicting progression-free survival.
None of the EGFR mutations initially detected in cfDNA
before treatment were detected 2 months after EGFR-TKI
therapy and partial response. Since the initial tumor size
and stage did not correlate with the detection rate, this re-
sult suggests that the amount of actively proliferating
tumor cells, rather than the tumor burden, could affect the
amount of circulating tumor DNA. Accordingly, in a previ-
ous CTC study, a 50% decline in CTCs within 1 week was
noted in one patient, with the nadir reached 3 months
after treatment, while the number of CTCs increased at
the time of clinical progression and declined again when
the tumor responded to subsequent chemotherapy [24]. It
was also evident that, although CTC detection was not as-
sociated with initial tumor burden, there was a close con-
cordance between tumor response and the number of
CTCs during treatment.
Finally, our results suggest that better processing of
plasma samples and on-site testing without necessity of
sample delivery can improve detection rate.
In summary, our results show that, although detec-
tion of EGFR mutations in cfDNA is possible in some
patients, more data are required to evaluate clinical ap-
plicability. Technical advances in sensitivity, stability
and standardization are also needed, as well as ad-
equate sample processing.
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